The 2-tier serology assay missed 85.7% of the cases of early Lyme disease with spirochetemia
Carl Tuttle
Hudson, NH
JAN 16, 2018 — Please see the letter below addressed to the TBD Working Group referencing ongoing attempts to suppress direct detection methods in the laboratory testing for Lyme disease.
Anyone wishing to contact the Lyme Disease Working Group can send an email to: tickbornedisease@hhs.gov
Letter to the Working Group:
I would like to call attention to the study below published in November of 2010 by Dr. Sin Lee identifying faulty serology tests for Lyme disease in 85.7% of the walk-in patients in the Emergency Room of Milford Hospital.
One month after publishing his paper (Dec 13, 2010) Dr. Lee received a termination of employment letter from the Director of Human Resources at Milford Hospital as they ordered the immediate shutdown of the molecular diagnostic laboratory. It appears that individuals at Yale Medical Group weren’t happy with the truth and wanted to end his work and shut down his lab sabotaging the development of a DNA sequencing test for Lyme disease diagnosis.
For those who haven’t made the connection:
Serology cannot be used to gauge treatment failure or success which makes it the ideal tool for concealing persistent infection perpetuating the thirty year dogma that chronic Lyme does not exist.
Did the scientists in Europe use Western blot or DNA sequencing to prove the Iceman contracted Lyme disease 5000 years ago? If DNA sequencing can be used to confirm Lyme disease in a dead man frozen 5000 years ago, why are we not trying to use the same technology to diagnose Lyme disease on those still walking?
Iceman Mummy May Hold Earliest Evidence of Lyme Disease
https://www.livescience.com/18704-oldest-case-lyme-disease-spotted-iceman-mummy.html
Dr. Lee went on to win a lawsuit against his employer’s irrelevant unsubstantiated accusations(Sin Hang Lee vs. Milford Hospital, Incorporated et al) and reopened his lab to continue his work. In 2014 Dr. Lee published a study of persistent infection while working on a project with the Centers for Disease Control. Once that study was published, the CDC stopped communicating with him.
“There are people who do not want to see the ugly truth which may be revealed by widespread use of direct detection tests.”
With early detection and treatment, eradication of infection is possible but faulty/misleading antibody tests are the root cause of unimaginable pain and suffering.
A Lyme patient in Norway won her recent lawsuit due to faulty/misleading antibody tests….
“On May 23rd, 2017, Seim was granted, in the District Court, 340,000 in court costs, and claims for expenses for up to 90,000”
BOTA BORRELIA – CURE LYME – Lyme patient receives compensation 10 years after inadequate treatment.
https://botaborrelia.wordpress.com/2018/01/09/bota-borrelia-cure-lyme-borreliapatient-far-ersattning-10-ar-efter-bristande-behandling-lyme-patient-receives-compensation-10-years-after-inadequate-treatment/
___________________________1. Dr. Lee’s 2010 Publication:
BMC Res Notes. 2010 Nov 1;3:273. doi: 10.1186/1756-0500-3-273.
Early Lyme disease with spirochetemia – diagnosed by DNA sequencing.
Lee SH1, Vigliotti VS, Vigliotti JS, Jones W, Williams J, Walshon J. https://www.ncbi.nlm.nih.gov/pubmed/21040573Abstract
BACKGROUND:
A sensitive and analytically specific nucleic acid amplification test (NAAT) is valuable in confirming the diagnosis of early Lyme disease at the stage of spirochetemia.
FINDINGS:
Venous blood drawn from patients with clinical presentations of Lyme disease was tested for the standard 2-tier screen and Western Blot serology assay for Lyme disease, and also by a nested polymerase chain reaction (PCR) for B. burgdorferi sensu lato 16S ribosomal DNA. The PCR amplicon was sequenced for B. burgdorferi genomic DNA validation. A total of 130 patients visiting emergency room (ER) or Walk-in clinic (WALKIN), and 333 patients referred through the private physicians’ offices were studied. While 5.4% of the ER/WALKIN patients showed DNA evidence of spirochetemia, none (0%) of the patients referred from private physicians’ offices were DNA-positive. In contrast, while 8.4% of the patients referred from private physicians’ offices were positive for the 2-tier Lyme serology assay, only 1.5% of the ER/WALKIN patients were positive for this antibody test. The 2-tier serology assay missed 85.7% of the cases of early Lyme disease with spirochetemia. The latter diagnosis was confirmed by DNA sequencing.
CONCLUSION:
Nested PCR followed by automated DNA sequencing is a valuable supplement to the standard 2-tier antibody assay in the diagnosis of early Lyme disease with spirochetemia. The best time to test for Lyme spirochetemia is when the patients living in the Lyme disease endemic areas develop unexplained symptoms or clinical manifestations that are consistent with Lyme disease early in the course of their illness.
__________________________2. Dr. Lee’s additional publication identifying chronic Lyme: (2014)
DNA sequencing diagnosis of off-season spirochetemia with low bacterial density in Borrelia burgdorferi and Borrelia miyamotoi infections.
https://www.ncbi.nlm.nih.gov/pubmed/24968274
_______________________At what point in time do we acknowledge that Lyme disease has been tenaciously mishandled to protect the long established racketeering scheme outlined in the Shrader & Associates RICO lawsuit;
You can read the court document here:
https://www.courthousenews.com/wp-content/uploads/2017/11/LymeDisease.pdf
Might I remind everyone reading this email that the Centers for Disease Control has aligned itself with the seven defendants identified in this racketeering lawsuit so if the CDC is allowed to oversee the future direction of Lyme per the recommendations/outcome of this TBD Working Group we are in for another thirty years of failure to control, treat and eliminate this 21st Century plague.
Sincerely,
Carl Tuttle
Lyme Endemic Hudson, NH
Madison Area Lyme Support Group 